Addressing Unmet Need in Diabetes/Obesity (BIO 2019)

Audio Link: Addressing Unmet Need in Diabetes/Obesity

BIO 2019
June 3-6, 2019 | Philadelphia, PA
3:00 PM–4:00 PM

Highly Prevalent Chronic Diseases


  • Danielle M. Marra, MS, MBA, Associate Principal, Cello Health BioConsulting, Previously Defined Health


  • Brian Bloomquist, Diabetes External Innovation, Eli Lilly and Company
  • Tomas Landh, Innovation Sourcing Vice President, Senior Principal Scientist R&D External Innovation Sourcing, Novo Nordisk A/S Denmark
  • Andrew Reaume, President & CEO, Melior Pharmaceuticals

With drug pipelines slimming down in the face of complex and costly Phase IIIs and investors weary of downstream market pressures, will the industry continue on its quest to find innovative solutions to Obesity and Diabetes? This panel session will explore the challenges of two highly correlated metabolic diseases, obesity and diabetes, and their potential solutions. The discussion will explore examples of current innovative drug programs that may be overcoming these obstacles, and where the current pipeline and ecosystem is falling short.